Skip to main content
main-content

Diabetes complications and comorbidities: Nephropathy

medwireNews top story

Prediabetes marks increased vascular risk

Cartoon of overweight man walking on a 'cardiovascular tightrope'

People who meet the criteria for prediabetes during the 3 years before a type 2 diabetes diagnosis have a higher burden of vascular disease than those who do not, research shows.

medwireNews top story

Hypoglycemia risk with even mild renal dysfunction in real-world practice

Human kidney cross section on scientific background. 3d illustration

A large observational study reveals a strong link between reduced kidney function and increased incidence of hypoglycemia in adults with diabetes in routine clinical practice.

medwireNews top story

‘Early therapeutic window’ highlighted for LADA

Open window

Optimal glycemic control during the first years after a latent autoimmune diabetes of adulthood diagnosis could prevent people’s microvascular complication risk from equaling that seen in those with type 2 diabetes, shows an analysis of the UKPDS.

medwireNews top story

CVD-REAL 3: Renal benefits of SGLT2 inhibitors confirmed in real-world study

Kidneys

Patients with type 2 diabetes who are treated with SGLT2 inhibitors in routine clinical practice have a lower rate of kidney function decline and a reduced risk for adverse renal events compared with those given other glucose-lowering drugs, researchers report.

medwireNews top story

Nonalbuminuric CKD risks confirmed in type 2 diabetes

Heart kidney and nerves

People with type 2 diabetes and reduced kidney function in the absence of albuminuria have an increased risk for mortality and major adverse cardiovascular events, despite a low risk for end-stage renal disease, research shows.

Expert opinion editorial

Cardiorenal syndromes and SGLT2 inhibitor usage

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity [read more].

Get more on: SGLT2 inhibitors | Nephropathy | Cardiovascular disease 

medwireNews top story

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Kidneys

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

Ask the expert video

Team-based care for patients with type 2 diabetes and kidney disease

Team-based care for patients with type 2 diabetes and kidney disease

WATCH | Nephrologist Katherine Tuttle and Primary Care Physician Jay Shubrook discuss discuss referrals to nephrology for patients with comorbid diabetes and kidney disease (8:38).

Get more on: Nephropathy | Diabetes complications and comorbidities | Ask the expert videos

medwireNews top story

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

Pills in hand

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

Interactive patient case study

Renal complications in diabetic ketoacidosis

Renal complications in diabetic ketoacidosis

This 15-minute case presents likely causes of renal complications in diabetic ketoacidosis and explains how to identify the signs and symptoms of renal complications to ensure early initiation of appropriate treatment.

Get more on: Diabetic ketoacidosis | Pediatric diabetes | Nephropathy

medwireNews

05-05-2020 | Prediabetes | Highlight | News

Prediabetes marks increased vascular risk

People who meet the criteria for prediabetes during the 3 years before a type 2 diabetes diagnosis have a higher burden of vascular disease than those who do not, research shows.

04-29-2020 | Nephropathy | News

Real-world data back renal benefits with SGLT2 inhibition

Use of sodium-glucose cotransporter 2 inhibitors is associated with a reduced risk for renal events in people with type 2 diabetes in clinical practice, say researchers.

04-23-2020 | GLP-1 agonists | News

Real-world evidence for renoprotective effects of GLP-1 receptor agonists

People with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists have a lower risk for serious renal adverse events than those given dipeptidyl peptidase-4 inhibitors, indicate results from a Scandinavian real-world study.

Interactive patient case study

12-21-2018 | Ketoacidosis | Case study | Link

Renal complications in diabetic ketoacidosis

Develop and test your knowledge on the renal complications associated with diabetic ketoacidosis through this practical example and self-assessment authored by Professor Francesco Chiarelli. This 15-minute case presents likely causes of renal complications in diabetic ketoacidosis and explains how to identify the signs and symptoms of renal complications to ensure early initiation of appropriate treatment.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

10-23-2018 | Complications | Article

Validation of time in range as an outcome measure for diabetes clinical trials

Beck RW et al. Diabetes Care 2018: dc181444. doi: 10.2337/dc18-1444

09-08-2018 | Nephropathy | Review | Article

Metabolic abnormalities in diabetes and kidney disease: Role of uremic toxins

Koppe L, Fouque D, Soulage CO. Curr Diab Rep 2018; 18: 97. doi: 10.1007/s11892-018-1064-7

08-15-2018 | Nephropathy | Review | Article

Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis

Iyengar R, Franzese J, Gianchandani R. Curr Diab Rep 2018; 18: 75. doi: 10.1007/s11892-018-1044-y

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits